Opendata, web and dolomites

KlotoDx

KlotoDx A quick and cost-effective near-patient tool to identify sepsis-related bacteria and antibiotic resistances

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 KlotoDx project word cloud

Explore the words cloud of the KlotoDx project. It provides you a very rough idea of what is the project "KlotoDx" about.

worldwide    disruptive    care    leukemia    biodesign    first    edge    artificial    algorithms    time    detected    validated    healthcare    detection    antibiotic    characterization    boosts    efficient    70    plan    agents    primary    rna    diagnosis    place    sepsis    instrument    diagnostic    limited    disease    30    device    total    opportunity    cutting    feasibility    caused    investment    envision    resistance    culture    antimicrobial    enter    6m    death    solution    near    aand    diagnosed    detect    market    engineering    resistances    apl    hours    segment    adapt    acute    sme    expressed    perform    treatment    ribosomal    klotodx    broad    mostly    lethal    blood    takes    people    preliminary    efficiency    24    bacteria    rates    fast    causing    dramatically    promyelocytic    genes    identification    diagnostics    day    once    commercialize    patient    generation    manner    moirai    techniques    validate    bacterial    spectrum    house    antibiotics    platform    intelligence    appropriately    patients    reduce   

Project "KlotoDx" data sheet

The following table provides information about the project.

Coordinator
MOIRAI BIODESIGN S.L. 

Organization address
address: GRAN VIA CORTS CATALANES, 272, 8 4
city: BARCELONA
postcode: 8004
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.moiraibiodesign.com/index.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MOIRAI BIODESIGN S.L. ES (BARCELONA) coordinator 50˙000.00

Map

 Project objective

Sepsis is a common disease caused mostly by bacteria that affects about 30 M people each year worldwide. If not diagnosed on time and treated appropriately, it may be lethal in 30% of cases and the cost for the healthcare system if not detected within the first 24 hours can rise dramatically. Current diagnostic techniques used to detect bacteria in patients’ blood, and identify their antimicrobial resistances, are still based on blood culture which takes more than 1 day and has a very limited detection efficiency. Moirai Biodesign is currently engineering a whole new generation of RNA-based diagnostics using both our in-house and cutting-edge artificial intelligence algorithms to detect ribosomal RNA from bacterial agents and expressed bacterial genes associated to common antibiotic resistances and a patient’s blood sample. Our platform is a near-patient, fast, efficient and cost-effective solution for the early detection and characterization of sepsis-related bacteria which will improve patient’s treatment, avoid broad-spectrum antibiotics’ side-effects and dramatically reduce death rates. Our technology has been preliminary validated for the diagnosis of Acute Promyelocytic Leukemia (APL) and KlotoDx’s main goal is to further adapt, validate and commercialize our disruptive diagnosis device for the identification of sepsis-causing bacteria and their antibiotic resistance genes. To achieve it and place our disruptive near-patient solution in the healthcare market, we envision a total investment of around €2.3 M and we plan to reach the 70% (around €1.6M) by applying for a Phase 2 within the H2020 SME-Instrument programme, once we perform the feasibility study during Phase 1. The increasing need for early sepsis diagnosis aand its characterization in terms of antibiotic resistance boosts KlotoDx’s opportunity to enter the primary care segment in a very disruptive manner.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KLOTODX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KLOTODX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More